Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLiron HofstetterYBYotam BronsteinGIGilad Itchaki

Discussion

Loading...

Member takes

Overview

Observational analysis shows high response and survival rates in CLL patients treated with venetoclax, indicating effective therapy options.

Key Points

  • Overall response rate at 12 months was 98% in treatment-naïve patients and 95% in relapsed/refractory patients.
  • Median progression-free survival was 50.6 months for relapsed/refractory patients, affected significantly by genetic features.
  • Patients receiving venetoclax combined with obinutuzumab had favorable survival rates compared to monotherapy.
  • Serious adverse events occurred in 45% of treatment-naïve patients, primarily neutropenia and infections.

Cite This Study

Hofstetter et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85chttps://doi.org/10.1182/blood-2025-3893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single‐Center Comparative Analysis With Randomized Clinical Trials2025 · 1 citations
  2. 2Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers of slovakia2025
  3. 3First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025
  4. 4Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting2025 · 1 citations
  5. 5Real-world survival outcomes with first-line venetoclax therapy in AML2025